Free Trial

Induction Healthcare Group (INHC) Competitors

Induction Healthcare Group logo
GBX 8.67 -0.33 (-3.67%)
(As of 12/20/2024 03:08 AM ET)

INHC vs. RENX, COG, IQAI, FDBK, DVRG, TRLS, SENS, EMIS, CRW, and INS

Should you be buying Induction Healthcare Group stock or one of its competitors? The main competitors of Induction Healthcare Group include Renalytix (RENX), Cambridge Cognition (COG), IQ-AI (IQAI), Feedback (FDBK), DeepVerge (DVRG), Trellus Health (TRLS), Sensyne Health (SENS), EMIS Group (EMIS), Craneware (CRW), and Instem (INS). These companies are all part of the "health information services" industry.

Induction Healthcare Group vs.

Renalytix (LON:RENX) and Induction Healthcare Group (LON:INHC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, community ranking, profitability and institutional ownership.

Renalytix has a net margin of 0.00% compared to Induction Healthcare Group's net margin of -23.86%. Induction Healthcare Group's return on equity of -14.53% beat Renalytix's return on equity.

Company Net Margins Return on Equity Return on Assets
RenalytixN/A -1,073.18% -93.54%
Induction Healthcare Group -23.86%-14.53%-7.32%

Renalytix has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500. Comparatively, Induction Healthcare Group has a beta of -0.41, indicating that its share price is 141% less volatile than the S&P 500.

Renalytix received 9 more outperform votes than Induction Healthcare Group when rated by MarketBeat users. However, 93.33% of users gave Induction Healthcare Group an outperform vote while only 74.19% of users gave Renalytix an outperform vote.

CompanyUnderperformOutperform
RenalytixOutperform Votes
23
74.19%
Underperform Votes
8
25.81%
Induction Healthcare GroupOutperform Votes
14
93.33%
Underperform Votes
1
6.67%

28.4% of Renalytix shares are held by institutional investors. Comparatively, 46.3% of Induction Healthcare Group shares are held by institutional investors. 35.7% of Renalytix shares are held by insiders. Comparatively, 54.6% of Induction Healthcare Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Induction Healthcare Group has higher revenue and earnings than Renalytix. Induction Healthcare Group is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Renalytix£2.29M7.21-£33.46M-£0.24-41.46
Induction Healthcare Group£13.65M0.60-£3.25M-£0.03-289.00

In the previous week, Renalytix had 2 more articles in the media than Induction Healthcare Group. MarketBeat recorded 2 mentions for Renalytix and 0 mentions for Induction Healthcare Group. Renalytix's average media sentiment score of 0.49 beat Induction Healthcare Group's score of 0.00 indicating that Renalytix is being referred to more favorably in the media.

Company Overall Sentiment
Renalytix Neutral
Induction Healthcare Group Neutral

Summary

Induction Healthcare Group beats Renalytix on 8 of the 15 factors compared between the two stocks.

Get Induction Healthcare Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for INHC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

INHC vs. The Competition

MetricInduction Healthcare GroupHealth Information Services IndustryMedical SectorLON Exchange
Market Cap£8.14M£196.58M£5.14B£1.91B
Dividend YieldN/A6.94%5.09%5.45%
P/E Ratio-289.00540.3890.051,867.09
Price / Sales0.60285.021,116.25393,302.55
Price / Cash2.6847.1443.1028.64
Price / Book0.395.074.782.81
Net Income-£3.25M-£8.11M£120.31M£155.77M
7 Day Performance-8.74%-0.95%-1.92%-2.02%
1 Month Performance-3.67%5.83%13.65%21.67%
1 Year Performance-60.59%6.32%28.34%29.76%

Induction Healthcare Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
INHC
Induction Healthcare Group
N/AGBX 8.67
-3.7%
N/A-61.5%£8.14M£13.65M-289.0074Gap Down
RENX
Renalytix
N/AGBX 9.50
flat
N/A-28.9%£15.76M£2.29M-40.63102News Coverage
COG
Cambridge Cognition
N/AGBX 30.50
-1.6%
N/A-37.9%£12.79M£13.08M-751.2580News Coverage
Gap Up
High Trading Volume
IQAI
IQ-AI
N/AGBX 1.40
-12.5%
N/A-63.0%£3.10M£538,190.00-13.676Gap Up
FDBK
Feedback
N/AGBX 17.75
flat
N/A-75.9%£2.37M£1.18M-71.0024
DVRG
DeepVerge
N/AGBX 0.15
flat
N/AN/A£1.14M£12.41M-15.0073
TRLS
Trellus Health
N/AGBX 0.58
-8.0%
N/A-82.9%£929,000.00£35,000.00-19.1731Gap Down
High Trading Volume
SENS
Sensyne Health
N/AGBX 0.35
-33.3%
N/AN/A£583,000.00£7.81M-0.0270Gap Down
EMIS
EMIS Group
N/AN/AN/AN/A£1.23B£176.86M4,085.111,560
CRW
Craneware
1.4374 of 5 stars
GBX 2,300
-1.7%
GBX 2,700
+17.4%
+22.9%£812.82M£189.27M8,846.15734
INS
Instem
N/AGBX 830
flat
N/AN/A£199.62M£61.63M5,928.57500News Coverage

Related Companies and Tools


This page (LON:INHC) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners